Because the model was voluntary for Part D plan sponsors, CMS designed financial incentives to encourage plan participation
Sources Dietary Recommendations for the Management of Gastrointestinal Symptoms in Patients Treated with GLP-1 Receptor Agonist (PMC) Application of nutrition interventions with GLP-1 based therapies: a narrative review (PMC) Endocrine Society: Consuming more protein may protect patients taking anti-obesity drug from muscle loss (ENDO 2025) Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with GLP-1 Receptor Agonists (PMC) MedlinePlus: Fiber MedlinePlus: High-fiber foods Mayo Clinic Health System: Assessing protein needs Mayo Clinic: High-protein snacks Therapeutic Benefits and Dietary Restrictions of Fiber Intake (PMC)
To assess the associations of semaglutide with incident CUD (first time diagnosis of CUD), the study population included 83,189 patients who had active medical encounters for the diagnosis of obesity in 6/202112/2022, were for the first time (new users design) prescribed semaglutide or non-GLP-1RA anti-obesity medications (bupropion, naltrexone, orlistat, topiramate, phentermine) [39] during 6/2021-12/2022 (time zero or index event), had no diagnosis of CUD on or before the index event and had a diagnosis of at least one of obesity-associated comorbidities (T2D, hypertension, hypercholesterolemia, hyperlipidemia, heart diseases, stroke) on or before the index event
Do not eat any solid food
Guzman-Perez, A
